cystrin - arama sonuçları

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

acetylcysteine-link injection acetylcysteine 2g/10ml concentrated injection ampoule

link medical products pty ltd t/a link pharmaceuticals - acetylcysteine, quantity: 2 g - injection, concentrated - excipient ingredients: disodium edetate; water for injections; sodium hydroxide - antidote for paracetamol poisoning. ,acetylcysteine is indicated in the treatment of paracetamol overdose to protect against hepatotoxity.

ABD - İngilizce - NLM (National Library of Medicine)

cysteine hydrochloride injection

baxter healthcare corporation - cysteine hydrochloride (unii: zt934n0x4w) (cysteine - unii:k848jz4886) - cysteine hydrochloride injection, usp is indicated for use as an additive to amino acids solutions to meet nutritional requirements of neonates (preterm and term infants less than one month of age) requiring total parenteral nutrition. cysteine hydrochloride injection, usp is contraindicated in: risk summary cysteine hydrochloride injection, usp for use as an additive to amino acid solutions to meet nutritional requirements is not indicated for use in adults. appropriate administration of cysteine hydrochloride injection, usp is not expected to cause major birth defects, miscarriage or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with cysteine hydrochloride. risk summary cysteine hydrochloride injection, usp is used as an additive to amino acid solutions to meet nutritional requirements of neonates requiring total parenteral nutrition and is not indicated for use in adults. there are no data on the presence of cysteine hydrochloride in human or animal milk or the effects on milk production. data available on the effects of cysteine hydrochloride on infants, either directly or through breastmilk, do not suggest a significant risk of adverse reactions from exposure. cysteine hydrochloride injection, usp is indicated for use as an additive to amino acid solutions to meet the nutritional requirements of neonates, including preterm infants, requiring total parenteral nutrition. the safety profile for cysteine hydrochloride injection, usp use in neonates includes risks of acid-base imbalance and hepatobiliary dysfunction. acid-base imbalance, including metabolic acidosis, and liver dysfunction may occur with cysteine hydrochloride injection, usp administration in preterm infants. frequent clinical and laboratory assessments are necessary to monitor and manage fluid balance, electrolyte concentrations, liver tests, and acid-base balance during parenteral nutrition therapy [see warnings and precautions (5.4)]. hyperammonemia is of special significance in neonates. this reaction appears to be related to a deficiency of the urea cycle amino acids of genetic or product origin. it is essential that blood ammonia be measured during treatment [see warnings and precautions (5.5)]. because of immature renal function, neonates including preterm infants, receiving prolonged parenteral nutrition with cysteine hydrochloride injection, usp may be at higher risk of aluminum toxicity [see warnings and precautions (5.7)].